Immuno-Biological Laboratories Co., Ltd. (JP:4570)

:4570

4570

Immuno-Biological Laboratories Co., Ltd.

RESEARCH TOOLSreports

Want to see JP:4570 full AI Analyst Report?

Immuno-Biological Laboratories Co., Ltd. (4570) Price & Analysis

0 Followers

4570 Stock Chart & Stats

¥1404.00

¥18.00(3.96%)

At close: Jan 08 4:00 PM EST

¥1404.00

¥18.00(3.96%)

Day’s Range― - ―

52-Week Range¥464.00 - ¥3,820.00

Previous CloseN/A

Volume75.00K

Average Volume (3M)23.51K

Market Cap

¥9.33B

Enterprise Value¥9.24B

Total Cash (Recent Filing)¥903.75M

Total Debt (Recent Filing)¥196.94M

Price to Earnings (P/E)28.4

Beta0.91

Next Earnings

Aug 06, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)27.81

Shares Outstanding9,314,590

10 Day Avg. Volume28,690

30 Day Avg. Volume23,506

Financial Highlights & Ratios

PEG Ratio1.18

Price to Book (P/B)6.78

Price to Sales (P/S)12.44

P/FCF Ratio46.69

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Conservative Balance Sheet / Low LeverageThe company's debt-to-equity near 0.10 and a strengthening equity base provide durable financial flexibility. Low leverage reduces refinancing and interest risk, supporting sustained R&D and product supply investment and resilience through industry cycles over the next several months.

High And Sustainable MarginsVery high gross margins and healthy operating/net margins imply product-level pricing power and a favorable cost structure typical of specialty reagents. Strong margins support reinvestment and return on capital and are likely durable because sales are largely repeat consumables used in labs.

Strong Free Cash Flow GenerationRobust operating and free cash flow that tracks earnings closely provides self-funded capacity for capex, working capital and R&D. High free cash conversion improves capital allocation optionality and lowers reliance on external financing over a multi-month horizon.

Bears Say

Historical Profitability VolatilityA recent history of deep losses and a turnaround raises durability risk: earnings may revert if product demand, pricing, or research budgets shift. Investors should note that a strong latest year does not erase past volatility and cyclical exposures inherent in reagents and diagnostics markets.

Small Scale / Limited Commercial FootprintA small headcount implies limited salesforce and operational scale, increasing single-product and customer concentration risk. Scaling international distribution, expanding commercial reach, and sustaining large R&D programs may be harder and slower versus larger peers.

Modest Revenue GrowthTop-line growth is modest which can constrain long-term earnings leverage. In a specialty reagents business, slow revenue expansion limits ability to spread fixed costs and fund accelerated R&D or commercial expansion, keeping returns and scale improvements incremental.

4570 FAQ

What was Immuno-Biological Laboratories Co., Ltd.’s price range in the past 12 months?

Immuno-Biological Laboratories Co., Ltd. lowest stock price was ¥464.00 and its highest was ¥3820.00 in the past 12 months.

What is Immuno-Biological Laboratories Co., Ltd.’s market cap?

Immuno-Biological Laboratories Co., Ltd.’s market cap is ¥9.33B.

When is Immuno-Biological Laboratories Co., Ltd.’s upcoming earnings report date?

Immuno-Biological Laboratories Co., Ltd.’s upcoming earnings report date is Aug 06, 2026 which is in 59 days.

How were Immuno-Biological Laboratories Co., Ltd.’s earnings last quarter?

Immuno-Biological Laboratories Co., Ltd. released its earnings results on May 13, 2026. The company reported ¥8.68 earnings per share for the quarter, beating the consensus estimate of N/A by ¥8.68.

Is Immuno-Biological Laboratories Co., Ltd. overvalued?

According to Wall Street analysts Immuno-Biological Laboratories Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Immuno-Biological Laboratories Co., Ltd. pay dividends?

Immuno-Biological Laboratories Co., Ltd. pays a Notavailable dividend of ¥7.441 which represents an annual dividend yield of N/A. See more information on Immuno-Biological Laboratories Co., Ltd. dividends here

What is Immuno-Biological Laboratories Co., Ltd.’s EPS estimate?

Immuno-Biological Laboratories Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Immuno-Biological Laboratories Co., Ltd. have?

Immuno-Biological Laboratories Co., Ltd. has 9,314,590 shares outstanding.

What happened to Immuno-Biological Laboratories Co., Ltd.’s price movement after its last earnings report?

Immuno-Biological Laboratories Co., Ltd. reported an EPS of ¥8.68 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.601%.

Which hedge fund is a major shareholder of Immuno-Biological Laboratories Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4570

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Immuno-Biological Laboratories Co., Ltd.

Immuno-Biological Laboratories Co., Ltd. engages in the research, development, manufacturing, and supply of various immunological research reagents worldwide. The company offers ELILSA, an assay kit to quantitatively measure targeted substances; and support research services on Alzheimer's disease, metabolic syndrome, and cancer, as well as customized services for production of customized antibodies and development of ELISA systems. It also provides LipoSEARCH, a customized services for profiling and analyzing of lipoprotein through gel-filtration high performance liquid chromatography method that can profile various clinical samples, such as tiny plasma or serum samples from both small animals and human beings for broad range of research fields including lipid metabolism, development of drugs for life-style related diseases, development of functional supplemental foods, and clinical studies. In addition, the company offers LipoTEST, a support tool for diagnostic and health checks at animal clinics; and customized biomarker testing services for Life-style related diseases. Further, it operates protein production business using transgenic silkworms for manufacturing of antibodies for research reagents and diagnostic products; human collagen for cosmetic materials; development of proteins for use in drugs; and other proteins production. The company was incorporated in 1982 and is headquartered in Fujioka, Japan.